<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2000</study_start_year><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2020221</full_dataset_link><location>Japan</location><study_start_month>4</study_start_month><keyword>Irinotecan</keyword><keyword>Leucovorin</keyword><keyword>Irinotecan, leucovorin, fluorouracil, PhaseI/II, colorectal cancer,</keyword><keyword>Fluorouracil</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer</name><description>We performed a phase I/II study of CPT-11/5FU/l-LV in advanced colorectal cancer, to determine the optimal dose of CPT-11 and to estimate the safety and efficacy of this regimen</description><dates><creation>2000-04-15</creation></dates><accession>2020221</accession><cross_references><ClinicalTrials___gov>NCT00209625</ClinicalTrials___gov></cross_references></HashMap>